Context Therapeutics Archives

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Published on : April 11, 2022April 11, 2022 Published by : BioBuzz Media

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Context Therapeutics® Strengthens Research & Development Team

Published on : January 6, 2022March 2, 2022 Published by : BioBuzz Media

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D. Context also announced the planned retirement of its current Head of CMC, Bill Rencher, Ph.D., who will move into an advisory role with the Company.

Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Published on : December 13, 2021December 13, 2021 Published by : BioBuzz Media

Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021 San Antonio Breast Cancer Symposium (SABCS).

Context Therapeutics Doses First Patient in Breast Cancer Trial

Published on : October 28, 2021October 28, 2021 Published by : Alex Keown

Coming off a $28.75 million initial public offering last week, Context Therapeutics dosed its first patient in a mid-stage breast cancer study assessing the combination of the progesterone receptor ONA-XR in combination with an estrogen receptor antagonist.

Context Therapeutics® and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone

Published on : August 25, 2021August 25, 2021 Published by : BioBuzz Media

Context Therapeutics Inc., a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, today announced the successful completion of ONA-XR (onapristone extended release) manufacturing process optimization pursuant to the collaboration agreement entered into between the parties in March 2020.